We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merck (MRK) Ascends While Market Falls: Some Facts to Note
Read MoreHide Full Article
Merck (MRK - Free Report) ended the recent trading session at $94, demonstrating a +0.87% swing from the preceding day's closing price. The stock's change was more than the S&P 500's daily loss of 1.78%. Meanwhile, the Dow experienced a drop of 0.99%, and the technology-dominated Nasdaq saw a decrease of 2.61%.
Shares of the pharmaceutical company witnessed a gain of 3.93% over the previous month, beating the performance of the Medical sector with its gain of 0.26% and the S&P 500's loss of 3.48%.
The investment community will be paying close attention to the earnings performance of Merck in its upcoming release. The company's earnings per share (EPS) are projected to be $2.16, reflecting a 4.35% increase from the same quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $15.75 billion, down 0.16% from the year-ago period.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $9.01 per share and a revenue of $65.19 billion, representing changes of +17.78% and +1.6%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for Merck. Such recent modifications usually signify the changing landscape of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. The Zacks Consensus EPS estimate has moved 1.95% lower within the past month. As of now, Merck holds a Zacks Rank of #4 (Sell).
Investors should also note Merck's current valuation metrics, including its Forward P/E ratio of 10.34. This indicates a discount in contrast to its industry's Forward P/E of 14.5.
Meanwhile, MRK's PEG ratio is currently 0.81. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Large Cap Pharmaceuticals was holding an average PEG ratio of 1.44 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 146, this industry ranks in the bottom 42% of all industries, numbering over 250.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Merck (MRK) Ascends While Market Falls: Some Facts to Note
Merck (MRK - Free Report) ended the recent trading session at $94, demonstrating a +0.87% swing from the preceding day's closing price. The stock's change was more than the S&P 500's daily loss of 1.78%. Meanwhile, the Dow experienced a drop of 0.99%, and the technology-dominated Nasdaq saw a decrease of 2.61%.
Shares of the pharmaceutical company witnessed a gain of 3.93% over the previous month, beating the performance of the Medical sector with its gain of 0.26% and the S&P 500's loss of 3.48%.
The investment community will be paying close attention to the earnings performance of Merck in its upcoming release. The company's earnings per share (EPS) are projected to be $2.16, reflecting a 4.35% increase from the same quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $15.75 billion, down 0.16% from the year-ago period.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $9.01 per share and a revenue of $65.19 billion, representing changes of +17.78% and +1.6%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for Merck. Such recent modifications usually signify the changing landscape of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. The Zacks Consensus EPS estimate has moved 1.95% lower within the past month. As of now, Merck holds a Zacks Rank of #4 (Sell).
Investors should also note Merck's current valuation metrics, including its Forward P/E ratio of 10.34. This indicates a discount in contrast to its industry's Forward P/E of 14.5.
Meanwhile, MRK's PEG ratio is currently 0.81. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Large Cap Pharmaceuticals was holding an average PEG ratio of 1.44 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 146, this industry ranks in the bottom 42% of all industries, numbering over 250.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.